Phase IV trial data reveals the drug helps patients achieve LDL-C goals with reduced muscle pain, bolstering its market position.
Zilebesiran, a twice-yearly injection, will be tested in 11,000 high-risk patients following promising mid-stage results.
New analyses from the REDUCE-IT trial show a 9% reduction in hospitalizations, bolstering the drug's profile amid ongoing generic competition.
Long-term study data presented at a major cardiology conference reinforces the drug's potential in treating a rare heart condition.
Financing deal carries risk of 46% equity dilution, coupled with a 1-for-7 reverse stock split to maintain Nasdaq listing.
Aficamten proves superior to metoprolol for hypertrophic cardiomyopathy, positioning the drug for a potential shift in treatment standards.
Shares soared over 36% after the European Commission authorized GOHIBIC for treating critically ill COVID-19 patients.
The new subcutaneous autoinjector offers a more convenient weekly maintenance option for patients after initial IV treatment.